Selected article for: "disease outbreak and mortality infection"
Author: Sahu, Kamal Kant; Mishra, Ajay Kumar; Raturi, Manish; Lal, Amos; George, Anu Anna; Martin, Dr. Kevin; Sargent, Dr. Jennifer; Mishra, Ajay; Martin, Kevin; Sargent, Jennifer
Title: Current Perspectives of convalescent plasma therapy in COVID-19
  • Cord-id: j3755ixl
  • Document date: 2020_11_10
    • ID: j3755ixl
    Snippet: The outbreak of the coronavirus disease 2019 (COVID-19) has posed an unprecedented challenge to the health care communities across the globe. As of December 2020, a total of 69,874,432 confirmed COVID-19 cases with 1,553,000 deaths have been reported. Different regions of the world have reported varying intensity of COVID-19 severity. The disease burden for COVID-19 depends on multiple factors like the local infection rate, susceptible population, mortality rate, and so on. The COVID-19 pandemic
    Document: The outbreak of the coronavirus disease 2019 (COVID-19) has posed an unprecedented challenge to the health care communities across the globe. As of December 2020, a total of 69,874,432 confirmed COVID-19 cases with 1,553,000 deaths have been reported. Different regions of the world have reported varying intensity of COVID-19 severity. The disease burden for COVID-19 depends on multiple factors like the local infection rate, susceptible population, mortality rate, and so on. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. As of today, there is a lack of definitive treatment options for COVID-19 pneumonia. In search of alternative options, few drugs are being tested for their efficacy and repurposing. Preliminary reports have shown positive outcomes with Remdesivir and tocilizumab, but this needs further confirmation. Recently, the therapeutic application of Convalescent Plasma therapy in critically ill patients suffering from COVID-19 has gained momentum. We hereby discuss the convalescent plasma as a potential therapeutic option, its challenges of finding the ideal donors, transfusion medicine responsibilities, and the current global experience with its use. (www.actabiomedica.it)

    Search related documents:
    Co phrase search for related documents
    • abo compatible and acute lung injury: 1, 2
    • abo compatible and acute respiratory syndrome: 1, 2
    • abo compatible and acute trali lung injury: 1
    • abo compatible convalescent plasma and access program: 1, 2
    • abo compatible convalescent plasma and acute lung injury: 1, 2
    • abo compatible convalescent plasma and acute respiratory syndrome: 1
    • abo compatible convalescent plasma and acute trali lung injury: 1
    • access program and acute ards respiratory distress syndrome: 1
    • access program and acute lung injury: 1, 2
    • access program and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • access program and acute trali lung injury: 1
    • actual clinical and acute ards respiratory distress syndrome: 1
    • actual clinical and acute respiratory syndrome: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and adjunct treatment: 1, 2, 3
    • acute lung injury and adaptive immunity: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adjunct treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10